Systemic lupus erythematosus (SLE), or lupus, is a chronic complex autoimmune disease for which there is no cure. It is characterized by B and T cell hyperactivation, overproduction of autoantibodies, and the deposition of immune complexes in various tissues and organs. The symptoms of lupus among patients are highly heterogeneous, which may include skin rash, arthritis, pericarditis, neuropsychiatric disorders, and nephritis. The Lupus Foundation of America estimates that 1.5 million Americans and at least five million people worldwide have a form of lupus.^[@ref1]^ Lupus affects mostly women of childbearing age and has a significantly higher prevalence among African Americans.^[@ref2]^ According to a report by the U.S. Centers for Disease Control and Prevention in 2002, the death rates attributed to lupus have increased by approximately 70% over a 20-year period among African American women aged 45--64 years.^[@ref3]^

Nephritis is one of the most damaging complications of lupus. It is the leading cause of morbidity and mortality among lupus patients. Around 35% adult lupus patients in the U.S. have clinical evidence of nephritis at the time of diagnosis. An additional 15--25% patients will develop nephritis within 10 years of their initial diagnosis.^[@ref4]^ Lupus nephritis (LN) is initiated by abnormal immune complex deposition on the basement membrane of renal glomeruli and the subsequent activation of the immune effector cells (*e*.*g*., macrophages and neutrophils), leading to damage of the renal tissues.^[@ref5]^ If not effectively managed, LN can progress rapidly to impair renal function and eventually result in kidney failure.^[@ref6]^

Among the limited treatment options,^[@ref7]^ glucocorticoid (GC) is one of the most potent and widely used classes of medication for lupus. According to the American College of Rheumatology's recent guidelines,^[@ref4],[@ref8]^ a pulse GC treatment followed by low/high-dose daily GC plus an immunosuppressive is recommended as a standard treatment regimen for clinical management of LN.^[@ref9]^ Due to their potent anti-inflammatory efficacy and the lack of alternatives,^[@ref10],[@ref11]^ GCs continue to be the mainstay for clinical management of lupus symptoms.^[@ref4],[@ref8]^ Some lupus pathologies, such as arthritis and skin rash, can be effectively managed with short-term GC treatment. Serious lupus complications, including progressive nephritis, however, necessitate long-term GC therapy, which is often associated with severe adverse events involving the musculoskeletal, endocrinal, hematopoietic, and cardiovascular systems.^[@ref12]^

The diverse biological effects of GCs are thought to be mediated *via* transrepression, which elicits GC's anti-inflammatory effects, and transactivation, which is responsible for the GC-associated side effects.^[@ref13]^ Selective glucocorticoid receptor modulators (SEGRMs) that can preferentially activate the transrepression relative to the transactivation pathway have been developed.^[@ref14],[@ref15]^ These compounds, however, do not exhibit strict pathway selectivity and still produce GC-related side effects.^[@ref13],[@ref16]^

Recognizing the therapeutic potential of GCs in the clinical management of LN, their accompanying severe toxicities, and the limited progress made in developing SEGRMs, we proposed to address this challenge through the development of a GC prodrug nanomedicine. Conceptually, this approach is based upon an inflammation-targeting mechanism, which we have discovered and termed "ELVIS".^[@ref17]^ It involves the Extravasation of the nanomedicine through Leaky Vasculature at sites of inflammation and its subsequent Inflammatory cell-mediated Sequestration, which would alter the pharmacokinetics/biodistribution profile of the parent drug, enabling its inflammatory tissues/organs specificity. When tested in a spontaneous LN mouse model (female NZB/W F1 mice), the GC prodrug (ZSJ-0228) nanomedicine we developed demonstrated superior therapeutic efficacy to dose equivalent dexamethasone 21-phosphate disodium (Dex) in ameliorating nephritis and improving kidney function, with no apparent GC toxicities.

Results {#sec2}
=======

The main objective of this project is to develop a GC prodrug nanomedicine with organ/tissue specificity to LN. We hypothesize that such an approach would potentiate the GC's efficacy and reduce systemic toxicities. As shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, the prodrug (ZSJ-0228) was designed by conjugating two dexamethasone molecules to the chain terminus of a short methoxy polyethylene glycol (mPEG, 1.9 kDa) *via* a hydrazone/glycine/glutamate linker system. The apparent amphiphilicity of the prodrug allows its spontaneous self-assembly into micelles in aqueous media, rendering the hydrophobic dexamethasone water-soluble. Additionally, due to the ELVIS mechanism, the systemically administered ZSJ-0228 would extravasate/filter at the LN pathology, be sequestered by inflammatory cells and activated kidney cells, and subsequently release dexamethasone within the endosomal/lysosomal compartments (*via* the acid-cleavable hydrazone bond) to exert its localized anti-inflammatory and immune-modulating effects without triggering systemic toxicities.

![Design of polyethylene glycol (PEG)-based amphiphilic dexamethasone prodrug ZSJ-0228, which can self-assemble into micelles in aqueous media. The oval shape highlights the dexamethasone structure.](nn-2018-01249s_0012){#sch1}

Synthesis of Amphiphilic Macromolecular Dexamethasone Prodrug (ZSJ-0228) {#sec2.1}
------------------------------------------------------------------------

ZSJ-0228 was successfully synthesized according to the route illustrated in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}. The identity of the polymeric prodrug and the absence of free Dex were confirmed using NMR, MS, and LC-MS/MS. The multistep synthesis is straightforward with high yield at each step. *tert*-Butyldimethylsilyl (TBS) was introduced in the first step to protect the 21-hydroxyl group and to improve solubility. The bulky presence of TBS sterically hinders access to the C-20 carbonyl group, resulting in the formation of a hydrazone bond predominantly at the C-3, not the C-20 carbonyl group. The presence of a local conjugation system also favors the C-3 hydrazone formation. Because of the use of hydrazone as the polymeric prodrug's activation trigger, multiple configurational isomers of compound **6** were formed, which could not be separated chromatographically. Mass spectroscopy (positive ion ESI) of the isomer mixture showed the molecular ion M + H^+^ at 1266.4 as a single peak (calculated molecular weight is 1265.7). After conjugation of compound **6** to mPEG-COOH and the subsequent removal of the TBS protection group, the prodrug ZSJ-0228 was prepared. The theoretical dexamethasone content in ZSJ-0228 was calculated as 26.7 wt %. After complete hydrolysis, HPLC analysis found 26.4 wt % of the prodrug we synthesized to be dexamethasone, suggesting ∼99% purity.

![Synthetic route for ZSJ-0228, a polyethylene glycol (PEG)-based amphiphilic dexamethasone prodrug. Reagents and conditions: 1. TBSCl (1.1 equiv), imidazole (2.0 equiv), DMF, 0 °C, 3 h, rt, 2 h, 98.5%; 2. NH~2~NH~2~ (3.0 equiv), HOAc (0.2 equiv), MeOH, rt, 5 h, 85.8% (brsm); 3. Fmoc-glycine (1.3 equiv), DCC (1.5 equiv), DMAP (0.3 equiv), DMF, 0 °C, 3 h, 84.5% (crude); 4. piperidine (3 equiv), dichloromethane; 0 °C, 3 h, 90.6%; 5. Fmoc-glutamic acid (0.48 equiv), DCC (1.4 equiv), HOBt (1.4 equiv), DMF, rt., 4 h, 86.5% (crude); 6. piperidine (5 equiv), dichloromethane; 0 °C, 3 h, 86.4%; 7. M-PEG-COOH (0.15 equiv), DCC (1.5 equiv), HOBt (1.5 equiv), DMF, rt., 24 h; 8. TBAF (20 equiv), THF, rt., 2 h, 77.8% for two steps. TBSCl: *tert*-butylchlorodimethylsilane; DCC: *N,N*′-dicyclohexylcarbodiimide; HOAc: acetic acid; DMAP: 4-dimethylaminopyridine; HOBt: 1-hydroxybenzotriazole; DMF: *N,N*-dimethylyformamide; TBAF: tetrabutylammonium fluoride; THF: tetrahydrofuran.](nn-2018-01249s_0013){#sch2}

Characterization of ZSJ-0228 Micelles {#sec2.2}
-------------------------------------

As expected, the conjugation of hydrophobic dexamethasone dimer to the hydrophilic mPEG led to the amphiphilic ZSJ-0228 prodrug's self-assembly into micelles upon direct dissolution in aqueous media. Using the pyrene-based fluorescence probe method, the critical micelle concentration (CMC) value of ZSJ-0228 was determined as 2.5 × 10^--4^ M. It is a relatively high CMC value, which will lead to the micelle's disintegration upon i.v. administration due to dilution in the blood. Dynamic light scattering (DLS) measurements ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A, Zetasizer Nano ZS90) revealed that the ZSJ-0228 can form micelles with an average micelle diameter of 33 nm and a net charge close to neutral. The DLS profile of the micelles was bimodal, suggesting the formation of heterogeneous particle populations. As shown in the transmission electron microscope (TEM) images, the micelles deposited on the substrate showed heterogeneity, with the majority of micelles showing an average diameter of ∼30 nm ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C) and the minority having a larger average diameter of ∼100 nm ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}D). Nanoparticle tracking analysis (NTA, Nanosight NS300) was employed as an additional method to measure the micelle size, distribution, and relative concentration. The NTA result ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B) seems to be in agreement with the DLS and TEM findings (as shown in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A, C, and D), showing that the diameter of micelles was mostly \<41 nm (90%) with a small population around 100 nm (10%, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B, inset).

![Characterization of ZSJ-0228 micelles. (A) DLS profile of ZSJ-0228 micelles. The measurement was performed in triplicate. (B) NTA measurement of ZSJ-0228 micelles. The measurements were repeated five times. (C) Representative transmission electron microscope (TEM) image of ZSJ-0228 micelles. The average diameter of the micelles is estimated to be ∼30 nm. (D) Representative TEM image of larger ZSJ-0228 micelle population with an estimated average diameter of ∼100 nm. Scale bar = 100 nm.](nn-2018-01249s_0001){#fig1}

![*In vitro* release of dexamethasone from ZSJ-0228 at different pH values. The experiment was done in acetate buffer (pH 4.5 and 5.0) and phosphate buffer (pH 6.5 and 7.4) at 37 °C. Pluronic F127 (1 wt % of dexamethasone) was added to create the "sink" condition. Each experiment was performed in triplicate. Results are expressed as mean ± SD.](nn-2018-01249s_0002){#fig2}

As the dexamethasone activation trigger, the hydrazone bond in the ZSJ-0228 design should only be cleaved under an acidic environment. This was confirmed in an *in vitro* prodrug activation experiment ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}) showing the near zero-order release of the conjugated dexamethasone with an almost constant rate at ∼1.32%/day and 0.96%/day for 4 weeks in the pH 4.5 and pH 5.0 acetate buffers, respectively. No dexamethasone release was detected in pH 6.5 and pH 7.4 buffers for the entire experiment duration.

ZSJ-0228 Effectively Ameliorated Proteinuria and Improved the Survival of NZB/W F1 Mice with Established Nephritis {#sec2.3}
------------------------------------------------------------------------------------------------------------------

The therapeutic effects of ZSJ-0228 were evaluated in NZB/W F1 female mice (∼28 weeks old) with fully developed nephritis (proteinuria ≥100 mg/dL for 2 weeks). The mice were given two monthly intravenous injections of ZSJ-0228 (28 mg/kg, dexamethasone equivalent). Dose equivalent daily Dex (1 mg/kg, dexamethasone equivalent, i.v.)^[@ref18]^ and monthly saline administration (i.v.) were used as controls. At the end of two months, all animals were euthanized. As shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A, the mice in the saline group maintained a 100% incident rate of proteinuria, and 9 out of 12 mice (75%) demonstrated increased proteinuria level over the course of the experiment, with Albustix readings increasing from 2 to 4. For the Dex treatment group, the level of proteinuria increased in 36% of the mice (Albustix reading increased from 2 to 4) and was normalized in 18% of the mice (Albustix reading decreased from 2 to 1), suggesting that the Dex treatment can partially impede LN progression. In the ZSJ-0228 treatment group, only one mouse showed an increased level of proteinuria, with an Albustix reading increased from 2 to 4. Three mice maintained the same level of proteinuria (Albustix reading at 2), and the levels of proteinuria for the rest of the mice (60%) was normalized with an Albustix reading at 0 or 1. This result is significantly better than the saline control (*P* \< 0.01), suggesting that the prodrug treatment is very effective in amelioration of LN.

![Monthly ZSJ-0228 treatment demonstrates superior therapeutic efficacy when compared to dose equivalent daily Dex treatment. (A) Monthly ZSJ-0228 treatment normalized albuminuria among 60% of NZB/W F1 mice (with established nephritis), while dose equivalent daily Dex treatment only normalized 18% at the end of the 2-month treatment. PT = pretreatment. The percentages shown accounted for those animals with an Albustix reading of 2 and above at the 8-week time point. Each data point represents an individual mouse. *P* = 0.003, Fisher's exact test. (B) Kaplan--Meier survival curves for ZSJ-0228, Dex, and saline groups. Only ZSJ-0228 treatment resulted in 100% survival after two months of treatment, which is significantly better than saline controls (\*, *P* \< 0.05). No significant difference between ZSJ-0228 and Dex groups was found (*P* = 0.17). Log-rank test with Bonferroni's pairwise comparison.](nn-2018-01249s_0003){#fig3}

ZSJ-0228-treated NZB/W F1 mice also had a significantly better survival rate than the saline control mice (*P* \< 0.05). Before the end of the treatment (mice at 36 weeks of age), a total of 42% of mice in the saline group died due to severe nephritis ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B). This is in general agreement with reports in the literature of the median survival of saline-treated NZB/W F1 female mice (∼35 weeks).^[@ref19]−[@ref22]^ In comparison, two out of 11 mice treated with Dex died, and all ZSJ-0228-treated mice survived. The apparent trend of the ZSJ-0228 group toward better survival rates than the Dex group did not reach statistical significance (*P* = 0.17). All deceased animals exhibited the highest level of proteinuria (Albustix reading of 4) before death.

To further validate the superior therapeutic efficacy of ZSJ-0228, kidneys isolated at necropsy were sectioned, stained with periodic acid--Schiff, and evaluated by a pathologist (K.W.F.), who was blinded to the grouping arrangement. The tissue sections were graded using a histopathologic scoring system with a 4-point scale.^[@ref20]^ Compared to the ZSJ-0228-treated mice, more than 40% of the saline and Dex-treated mice had a higher percentage of damaged glomeruli (scoring 3 and 4 points). Evidence of acute glomerular injury includes endocapillary hypercellularity as well as the presence of wire-loop lesions, hyaline thrombi (indicating immune complex deposition), cellular crescents, *etc.* ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). In contrast, only ∼11% of the mice in the ZSJ-0228-treated group were graded with severe glomerulonephritis (with the rest in the mild and moderate categories), which was much lower than that of the saline (∼43%) and Dex (∼44%) groups. In addition, when individual glomeruli were evaluated histologically, abnormities were observed in 26% of the glomeruli from the ZSJ-0228-treated mice, which is close to the frequency (21.6%) found in the NZW mice (healthy control, which do develop anti-dsDNA antibodies, high serum levels of retroviral gp70 antigen, and nephritis later in life).^[@ref23]^ Compared to this observation, 40% and 52% of the glomeruli in the Dex and saline groups were found to be abnormal, respectively. Though these differences are not statistically significant (*P* = 0.19), the apparent trend further supports the superior efficacy of ZSJ-0228 in treating LN ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}F).

![Histological evaluation of kidneys from different treatment groups. The tissues were formalin-fixed, sectioned (3 μm), and stained with periodic acid--Schiff (PAS) for visual examination and grading by a pathologist (K.W.F.), who was blinded to the group design. (A) PAS-stained kidney section from the saline group showing wire-loop lesions (arrow). (B) PAS-stained kidney section from the Dex-treated group showing a cellular crescent (arrow). (C) PAS-stained kidney section from the ZSJ-0228-treated group, showing less severe glomerular injury with a healthier appearance similar to the NZW control. (D) PAS-stained kidney section from NZW control group. Scale bar = 50 μm. (E) Fractions of mice in each group with mild, moderate, and severe renal disease. Results are expressed as percentage of mice with the indicated disease severity. (F) Average percentage of abnormal glomeruli found in each group. Results are expressed as mean ± SD. No statistically significant difference was found among the groups. *P* = 0.19, one-way analysis of variance (ANOVA) with Tukey's pairwise comparison.](nn-2018-01249s_0004){#fig4}

ZSJ-0228 Treatment Showed No Apparent GC Toxicities {#sec2.4}
---------------------------------------------------

The viability of HK-2 cells (an immortalized renal proximal tubule epithelial cell line from normal adult human kidney) was evaluated after 72 h of incubation with ZSJ-0228, Dex, and mPEG. As can be seen in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A, ZSJ-0228 and Dex showed minimal cytotoxicity to HK-2 cells within the tested range of dexamethasone equivalent concentrations (0.01--2000 μM). mPEG was also found to be nontoxic.

![Safety assessment of ZSJ-0228 treatment. (A) Impact of mPEG, ZSJ-0228, and Dex on HK-2 cell viability after 72 h of incubation, as assessed by the MTT assay. For ZSJ-0228 and Dex, they were tested at dexamethasone equivalent concentrations (0.01--2000 μM). mPEG was tested at ZSJ-0228 equivalent concentrations (0.005--1000 μM). Each ZSJ-0228 has one mPEG and two dexamethasone molecules. (B) Body weight (% of week 0) of NZB/W F1 mice during the two-month treatments with ZSJ-0228 and Dex (dexamethasone dose equivalent). Saline was used as a control. ZSJ-0228 treatment did not affect the mice body weight. An early trend of decreased body weight was observed in the Dex group, suggesting a potential adverse effect of the treatment. (C) ZSJ-0228 treatment is significantly better at preserving bone mineral density than Dex treatment and the saline controls. (D) ZSJ-0228-treated mice trended toward a higher bone volume/tissue volume than Dex treatment and saline controls (*P* = 0.69). (E) ZSJ-0228-treated mice have a significantly higher trabecular thickness value than Dex treatment and saline controls. (F) The average white blood cell (WBC) count of the ZSJ-0228-treated mice was similar to that of the saline group, but was significantly higher than the Dex group. (G) Total serum IgG levels for mice in ZSJ-0228 (*n* = 10), Dex (*n* = 11), and saline (*n* = 12) groups were determined by ELISA at pretreatment, 4-week, and 8-week time points. The ZSJ-0228 treatment did not significantly reduce total serum IgG levels, whereas Dex treatment did, suggesting potential immune suppression. (H) Different from Dex treatment, ZSJ-0228 treatment did not induce adrenal gland atrophy. For bone quality (C, D, and E), WBC counts (F), and adrenal gland weight (H) evaluations, samples were available for analysis only from the subset of mice surviving at the final time point (8-week): 10 mice for the ZSJ-0228 group, 9 mice for the Dex group, 7 mice for the saline group. For total serum IgG levels (G), the ZSJ-0228 group has 10 mice at 4-week and 8-week time points; the Dex group has 11 and 9 mice at the 4-week and 8-week time points, respectively; and the saline group has 11 and 7 mice at the 4-week and 8-week time points, respectively. Results are expressed as mean ± SD. Statistical analysis of data in panels C, E, and H was performed using the Kruskal--Wallis test with Bonferroni's pairwise comparison. For panels D and F, the statistical analysis was performed using one-way ANOVA with Tukey's pairwise comparison. For panel G, the statistical analysis was performed using the generalized estimating equation (GEE) method with Tukey's pairwise comparison. \*, *P* \< 0.05, \*\*, *P* \< 0.01, \*\*\*\*, *P* \< 0.0001.](nn-2018-01249s_0005){#fig5}

During the two-month treatment study, no significant difference in body weight was observed among ZSJ-0228, Dex, and saline groups ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B). On average, all tested groups maintained above 90% of original body weight at the end of the two-month treatments. Different from the saline and ZSJ-0228 groups, an early trend of body weight decrease was observed in the Dex group, suggesting potential adverse effects of the treatment ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B). It is important to note that several mice from the saline and Dex groups died earlier ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B) due to severe nephritis and significant loss of body weight (\>20%). Their body weight values at the time of death were recorded. If they would have lived at the end of the two-month treatment period, a significant difference among the three tested groups may have been observed.

One of the major adverse effects associated with GC use is osteopenia. To understand the impact of ZSJ-0228 treatment on the skeleton, we evaluated the femoral bone quality using high-resolution μ-CT (Skyscan 1172). The bone mineral density and trabecular thickness in the femoral trabecular bone of ZSJ-0228-treated mice were significantly higher than those from the saline- and Dex-treated groups ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}C and E; *P* \< 0.05). A trend toward higher trabecular bone volume/tissue volume values was also observed ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}D, *P* = 0.69).

Chronic exposure to GC therapy is known to be associated with systemic immunosuppression. To understand if ZSJ-0228 as a GC prodrug would be similarly immunosuppressive, we evaluated the total serum IgG level and the peripheral white blood cell (WBC) counts at designated time points. As shown in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}F, ZSJ-0228-treated mice exhibited similar WBC counts as the saline group, but the value is significantly higher than that of the Dex-treated mice (*P* \< 0.05). As shown in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}G, total serum IgG levels were not altered in the ZSJ-0228-treated mice during the treatment. In contrast, the animals treated with daily Dex administration had a significant drop of serum IgG value after only one month of treatment (*P* \< 0.001) and continued this significant decrease until the end of the experiment (*P* \< 0.0001). These data collectively suggest that different from the Dex treatment, ZSJ-0228 did not suppress the immune system of the NZB/W F1 mice.

GC exposure, even in the short term, is known to suppress the hypothalamic--pituitary--adrenal axis, leading to clinical atrophy of the adrenal gland.^[@ref24]^ To understand if ZSJ-0228 treatment would cause adrenal gland atrophy in NZB/W F1 mice, the adrenal glands from all treatment groups were isolated and weighed at necropsy. The mean value of adrenal gland mass in the Dex group was significantly lower than that from the ZSJ-0228 group ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}H; *P* \< 0.05). No significant difference in adrenal gland mass was found between the ZSJ-0228 and saline groups ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}H; *P* = 0.22). These data suggest that the treatment with ZSJ-0228 does not lead to adrenal gland atrophy.

ZSJ-0228 Treatment Ameliorates Renal Immune Complexes but Does Not Alter Serum Anti-dsDNA Level {#sec2.5}
-----------------------------------------------------------------------------------------------

GCs have been shown to exert some of their therapeutic effects on lupus partially through the down-regulation of anti-dsDNA antibody levels.^[@ref25]^ Therefore, it was important to evaluate whether ZSJ-0228 attained its therapeutic effect through this mechanism. As shown in [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}, ZSJ-0228 treatment showed no impact on serum anti-dsDNA IgG during the treatment. However, it was found to significantly reduce renal immune complex deposition when compared to the saline control. Daily Dex treatment, on the other hand, was found to significantly reduce serum anti-dsDNA IgG levels at 4 and 8 weeks post-treatment initiation (*P* \< 0.05), but had no impact on renal immune complex deposition. The apparent trend of NZW and ZSJ-0228 groups toward lower renal immune complex deposition than the Dex group did not reach statistical significance (*P* = 0.078 and *P* = 0.074, respectively). Collectively, these results suggest that the immunosuppressive effect of ZSJ-0228 is not systemic but is rather restricted to the inflamed kidneys.

![Effect of different treatments on renal immune complex deposition and serum anti-dsDNA IgG levels. ZSJ-0228 treatment was found to significantly reduce renal immune complex deposition. While Dex daily treatment significantly reduced the serum anti-dsDNA IgG level, it had no impact on renal immune complex deposition. (A) Representative kidney sections from each treatment group, immunohistochemically stained for renal deposition of anti-mouse IgG. Compared to NZW and ZSJ-0228 groups, more immune complexes were found in the kidney sections from the saline and Dex groups. Scale bar = 50 μm. (B) Quantification of kidney immune complex staining. Results are expressed as mean ± SD; \*, *P* \< 0.05, one-way ANOVA test with Tukey's pairwise comparison. (C) Serum anti-dsDNA IgG levels at the pretreatment, 4-week, and 8-week time points, as determined by an enzyme-linked immunosorbent assay. Results are expressed as mean ± SD; \*, *P* \< 0.05, \*\*, *P* \< 0.01, GEE method with Tukey's pairwise comparison.](nn-2018-01249s_0006){#fig6}

ZSJ-0228 Reduced Renal Macrophage Infiltration {#sec2.6}
----------------------------------------------

To understand ZSJ-0228's working mechanism, we examined the infiltration of macrophages into the kidney, an indicator of chronic renal inflammation. The macrophage marker F4/80 was used in kidney tissue sections from all the treatment groups ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}A). Quantification of F4/80 staining suggested that Dex treatment did not significantly reduce macrophage infiltration when compared to the saline control. In contrast, ZSJ-0228 treatment significantly lowered the renal macrophage levels when compared with Dex treatment and the saline control ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}B). These results suggested that the ZSJ-0228 treatment may partially exert its therapeutic effects through ameliorating macrophage infiltration to the kidneys.

![Impact of different treatments on renal macrophage infiltration. (A) Representative kidney sections from each treatment group, immunohistochemically stained for renal deposition of anti-mouse F4/80. Scale bar = 50 μm. (B) Quantification of immune complex staining. Results are expressed as mean ± SD; \*, *P* \< 0.05, Kruskal--Wallis test with Bonferroni's pairwise comparison.](nn-2018-01249s_0007){#fig7}

ZSJ-0228 Targeted the Nephrotic Kidneys in NZB/W F1 Mice {#sec2.7}
--------------------------------------------------------

To understand the therapeutic efficacy and reduced GC-associated toxicities of ZSJ-0228, the *in vivo* biodistribution of ZSJ-0228 was qualitatively analyzed using near-infrared optical imaging. Both NZB/W F1 and NZW mice (healthy control) received i.v. injections of IRDye 800 CW-labeled ZSJ-0228 (ZSJ-0228-IRDye). As shown in [Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}A, in NZB/W F1 mice, ZSJ-0228-IRDye primarily accumulated in the kidneys and could be detected for at least 4 days. ZSJ-0228-IRDye was also found to accumulate in NZW mice's kidneys, but the intensity of the signal was at a much lower level, especially at 4 days postadministration. These observations seem to suggest that the severe nephritis of NZB/W F1 mice may have contributed to the targeting and retention of ZSJ-0228 in the kidneys.

![Targeting and retention of ZSJ-0228 in the kidneys of NZB/W F1 mice. (A) Representative optical images of organs isolated from NZB/W F1 mice and NZW mice (healthy control). Images were obtained at 1 and 4 days post-i.v. injections of IRDye 800 CW-labeled ZSJ-0228 (ZSJ-0228-IRDye). Pseudo-color-coded signal intensity reflects the level of ZSJ-0228-IRDye within the organ examined. All the images were acquired under the same conditions and share the same pseudocolor scale. Ht, heart; Lv, liver; Kd, kidney; Sp, spleen; Lu, lung; BL, blood; BM, bone marrow. (B) Flow cytometry analysis of cells isolated from organs of NZB/W F1 and NZW mice at 1 and 4 days post-i.v. injections of Alexa Fluor 647-labeled ZSJ-0228 (ZSJ-0228-AF647). Results are expressed as mean ± SD; \*\*\*\*, *P* \< 0.0001, one-way ANOVA with Tukey's pairwise comparison.](nn-2018-01249s_0008){#fig8}

To better appreciate the kidney retention mechanism of ZSJ-0228 on the cellular level, Alexa Fluor 647-labeled ZSJ-0228 (ZSJ-0228-AF647) was i.v. administered to NZB/W F1 and NZW mice. All major organs, including kidneys, were processed for flow cytometry analysis at 1 and 4 days postinjection. As shown in [Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}B, ∼56% of kidney cells from NZB/W F1 mice were positive for ZSJ-0228-AF647, while only ∼38% of kidney cells from NZW mice were ZSJ-0228-AF647 positive. The amount of ZSJ-0228-AF647 positive cells in all the other organs was less than 10%. For NZW mice, the percentage of ZSJ-0228-AF647-positive cells at 4 days postinjection decreased significantly (to ∼23%, *P* \< 0.0001) when compared to the value at 1 day postinjection. No significant ZSJ-0228-AF647 positive cell reduction was observed in kidneys of NZB/W F1 mice from 1 to 4 days postinjection. These flow cytometry data confirm ZSJ-0228-AF647's targeting to the inflamed kidneys of NZB/W F1 mice found in the optical imaging study and attributes the prodrug's retention in the kidney to cell-mediated sequestration.

Profiling of Kidney Cells That Internalized ZSJ-0228 {#sec2.8}
----------------------------------------------------

Additional flow cytometry analysis was performed to further profile the ZSJ-0228-AF647 positive cells in the kidneys after systemic administration of the prodrug. In the nephrotic kidney, ∼70% of CD11b^+^ (myeloid) cells internalized ZSJ-0228-AF647 at 1 day postinjection; these cells include CD11c^+^ (dendritic cell), NK1.1^+^ (natural killer cell), Ly6G^+^ (neutrophil), and F4/80^+^ (macrophage) subphenotypes ([Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}A).^[@ref26]^ At 4 days postinjection, ∼50% of these cells still remain positive for the prodrug. In comparison, ∼30% of the myeloid cells in the NZW mice group internalized the prodrug at 1 day postinjection, and only one-third of the cells remained positive for the prodrug at 4 days postinjection. Moreover, ∼60% of the CD326^+^ (proximal tubular epithelium) and CD146^+^ (endothelium) cells in nephrotic kidneys retained ZSJ-0228-AF647 at 4 days postinjection, which is 50% higher than in the control kidneys. These results suggest that both inflammatory cells and resident renal cells (including CD326^+^ and CD146^+^ cells) in the nephrotic kidneys have sequestered ZSJ-0228 and retained it as compared to the control. To account for ZSJ-0228-AF647's cellular distribution pattern, ∼20--40% of the prodrug was found in the CD11b^+^ cells of the nephrotic kidney, with less than 10% in the control kidneys ([Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}B). Around 30--40% of ZSJ-0228-AF647 was internalized by the CD326^+^ cells of both NZB/W F1 and NZW mice, suggesting that the prodrugs primarily distribute to the renal myeloid cells and proximal tubular epithelium. The rest of the ZSJ-0228-AF647 positive cells remain unidentified due to the lack of specific markers.

![Profiling the cellular internalization and retention of ZSJ-0228 by kidney cells. Flow cytometry was used to analyze cells isolated from kidneys of NZB/W F1 and NZW mice at 1 and 4 days postinjection of ZSJ-0228-AF647. (A) Percentage of renal cells that internalized ZSJ-0228-AF647. (B) Percentage of ZSJ-0228-AF647 internalized by different cells in the kidney. Results are expressed as mean ± SD; \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001; \*\*\*\*, *P* \< 0.0001, one-way ANOVA with Tukey's pairwise comparison.](nn-2018-01249s_0009){#fig9}

To validate renal cells' sequestration of ZSJ-0228-AF647 (red) observed by flow cytometry, nephrotic kidneys were harvested, sectioned, and immunohistochemically stained at 1 day post-i.v. administration of the prodrug for confocal microscope analysis. As can be seen in [Figure [10](#fig10){ref-type="fig"}](#fig10){ref-type="fig"}, fluorescent signal colocalization of CD133 (injured/activated proximal tubular epithelial cell),^[@ref27]^ CD146 (endothelium), or CD11b (myeloid cells) with ZSJ-0228-AF647 was observed in both low- and high-magnification images. This confirms the sequestration of ZSJ-0228-AF647 by these cells in the nephrotic kidney, which further supports the findings in [Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}.

![Immunohistochemical analysis of kidney cells' sequestration of ZSJ-0228-AF647. NZB/W F1 mice were i.v. administered ZSJ-0228-AF647 (red) and euthanized at 1 day postinjection. Kidneys were sectioned and stained with anti-mouse CD133, CD146, and CD11b (green). Nuclei were stained with DAPI (blue). Merged images are shown in the right panels. The higher magnification (63×) images are shown within the lower magnification (10×) images at the lower left corner. Scale bar = 100 μm.](nn-2018-01249s_0010){#fig10}

Internalization Kinetics and Subcellular Location of ZSJ-0228 {#sec2.9}
-------------------------------------------------------------

As an immortalized renal proximal tubule epithelial cell (RPTEC) line from a normal adult human kidney, HK-2 cells can reproduce experimental results obtained with freshly isolated RPTECs on the basis of its histochemical, immunocytochemical, and functional characteristics.^[@ref28]^ As RPTEC represents one of the main cellular populations identified to sequester ZSJ-0228, an HK-2 cell culture was used to recapitulate the internalization kinetics of the prodrug and its subcellular location. Alexa Fluor 488-labeled ZSJ-0228 (ZSJ-0228-AF488) was used in this particular experiment. As shown in [Figure [11](#fig11){ref-type="fig"}](#fig11){ref-type="fig"}A, HK-2 cells rapidly internalized ZSJ-0228-AF488 and the fluorescent signal intensity increased over time. Inflammatory conditions are known to be associated with accelerated endocytosis.^[@ref29],[@ref30]^ The introduction of lipopolysaccharide (LPS), however, did not accelerate the internalization process as anticipated, suggesting it may not be sufficient to recapitulate the *in vivo* inflammatory environment.

![*In vitro* internalization kinetics and subcellular location of Alexa Fluor 488-labeled ZSJ-0228 in human proximal tubule epithelial (HK-2) cells. (A) Cellular internalization kinetics of ZSJ-0228-Alexa 488 by HK-2 cells with or without lipopolysaccharide (LPS, 10 μg/mL) activation over a 72 h time course. Results are expressed as mean ± SD. (B) Representative confocal images exhibiting internalization and subcellular trafficking of ZSJ-0228-AF488 in LPS-activated (10 μg/mL) HK-2 cells. LysoTracker DND-99 signal (red), ZSJ-0228-AF488 signal (green), DAPI signal (blue). Scale bar = 20 μm.](nn-2018-01249s_0011){#fig11}

To define the subcellular location of ZSJ-0228 in HK-2 cells, the cells were incubated with ZSJ-0228-AF488 and LysoTracker (lysosome marker, DND-99, red) and then examined under the confocal microscope. The partial colocalization of internalized ZSJ-0228-AF488 (green) with DND-99 (red) indicates that ZSJ-0228 was endocytosed and processed in the acidic lysosomal compartment, which is ideal for the hydrazone-based acid-cleavable ZSJ-0228 prodrug design ([Figure [11](#fig11){ref-type="fig"}](#fig11){ref-type="fig"}B).

Discussion {#sec3}
==========

Recognizing the potent anti-inflammatory and organ-saving efficacy of GCs in the clinical management of lupus and the notorious toxicities associated with their chronic use,^[@ref31]^ we proposed to develop a macromolecular prodrug nanomedicine of GCs in this study to incorporate inflammatory tissue-specificity to these drugs. By restricting GCs' systemic distribution, we hope to achieve organ/tissue-specific anti-inflammatory and immunosuppressive effects, which may potentiate their therapeutic efficacy and mitigate the adverse effects associated with GCs.

The validity of this proposed concept can be attributed to the discovery of an inflammation targeting mechanism, which has been termed ELVIS.^[@ref17]^ It is fundamentally different from the well-known EPR (enhanced permeability and retention) effect^[@ref32]^ in that the nanomedicine's retention at the inflammation is not mediated by faulty lymphatic drainage, but through the inflammatory cell (including infiltrates and activated resident cells)-mediated sequestration.

According to the ELVIS mechanism, we previously have developed a macromolecular prodrug of dexamethasone (P-Dex) using *N*-(2-hydroxypropyl) methacrylamide (HPMA) copolymer as the carrier. The prodrug was found to provide a potent and long-lasting anti-inflammatory effect in multiple inflammatory disease models, including the NZB/W F1 LN mice.^[@ref19],[@ref33]−[@ref36]^ Mechanistically, this pathophysiology-driven targeting of GC to nephritis is different from the active kidney-targeting drug delivery,^[@ref37],[@ref38]^ in which different targeting ligands (*e*.*g*., peptides, sugar, and folates) were employed to render the renal specificity.

While P-Dex's therapeutic efficacy in the lupus model was strong and sustained, it could only circumvent osteopenia, while other GC toxicities (*e*.*g*., immunosuppression and adrenal gland atrophy) persisted.^[@ref19]^ Optical imaging-based biodistribution study and flow cytometry analyses of cells from all major organs and tissues suggest that the persisted side effects may be attributed to the prodrug's internalization by circulating WBCs and the high-level deposition to the mononuclear phagocyte system (MPS, including phagocytic cells of the liver and spleen). This hypothesis was partially supported by the amelioration of splenomegaly in the P-Dex-treated animals.^[@ref19]^ We posit that these off-target distributions and gradual activation of P-Dex may have led to the sustained presence of dexamethasone in the serum. While it may be at a low concentration and not enough to cause skeletal deterioration, the serum dexamethasone level can be sufficient to elicit systemic immunosuppression and adrenal gland atrophy.^[@ref39]^

With these understandings, we proceed to develop the next-generation macromolecular GC prodrug, which is not only effective in resolving LN but also able to avoid typical GC adverse effects found with P-Dex. The focus of our effort is to further reduce dexamethasone levels in the serum by limiting the prodrug's sequestration by WBCs and its deposition to the MPS.

Our previous finding suggests that the use of PEG as a prodrug carrier may significantly delay cellular internalization when compared to the use of an HPMA copolymer carrier of the same size.^[@ref40]^ Therefore, we used PEG as the water-soluble drug carrier in the ZSJ-0228 design ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). The selection of low molecular weight mPEG 1900 was based upon the prior findings that polymeric prodrugs with the lowest molecular weight demonstrate the highest kidney exposure and relatively lower liver deposition.^[@ref41],[@ref42]^ PEGs with a lower molecular weight of 0.4 or 1 kDa were not selected because they are mostly in wax or liquid form, which can be difficult to handle and to purify during the synthesis. The amphiphilic structure of ZSJ-0228 allows its self-assembly into micelles in aqueous media. Using DLS, TEM and NTA methods, we determined that the ZSJ-0228 micelle's average hydrodynamic diameter was around 30 nm, which may lead to a long serum half-life should the micelle remain stable.^[@ref43]^ The CMC value of the micelle, however, was determined to be relatively high (2.5 × 10^--4^ M). These micelles will disintegrate upon i.v. administration and dilution, significantly reducing its half-life in circulation. We anticipate that a shorter serum half-life of ZSJ-0228 would limit its distribution to the liver and spleen when compared to P-Dex,^[@ref41],[@ref42]^ but still provide sufficient kidney exposure for therapeutic effects.

A hydrazone bond was used as the ZSJ-0228 prodrug's activation trigger. The linker's *in vitro* cleavage rate under acidic pH is relatively slow ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}) when compared to other hydrazone linker-based prodrug designs.^[@ref44]^ Such slow activation kinetics may be explained by the presence of a large conjugation system, which involves four double bonds including two C=C bonds within the A ring of dexamethasone, one C=N bond, one C=O bond, and the lone pair of sp^2^ electrons of the neighboring nitrogen. The large delocalization of electrons stabilizes the C-3 hydrazone and reduces the rate of C=N double-bond cleavage, which is responsible for the release of dexamethasone. When doxorubicin is conjugated to HPMA copolymer *via* a hydrazone bond,^[@ref44]^ such structural stabilization does not exist. The slow *in vitro* hydrazone bond cleavage, however, does not necessarily predict a slow *in vivo* prodrug activation. Also contributing to ZSJ-0228's *in vivo* activation is the pH value within lysosomal compartments, which can be significantly reduced under inflammatory conditions^[@ref45]^ and accelerate the hydrazone bond cleavage. For future prodrug design, other biochemical factors, such as the elevated presence of reactive oxygen species (ROS), which is often associated with inflammatory pathologies,^[@ref46]^ may also be considered as a trigger for prodrug activation at the site of inflammation.^[@ref47]^

Due to the use of hydrazone as an activation trigger, ZSJ-0228 should have multiple configurational isomers. Since the activation product from these isomers is the same (*i*.*e*., dexamethasone) and their ratio from different batches remains consistent, the presence of these isomers in ZSJ-0228 will not be a concern during the preclinical Chemistry, Manufacturing, and Controls development. Though not used in our synthesis, we are aware of the development of single molecular weight discrete PEG (dPEG), which has become commercially available. Different from traditional macromolecular prodrug design, the use of dPEG in the synthesis of ZSJ-0228 will produce a single molecular weight polymeric prodrug, which will further reduce potential regulatory hurdles during the product development.

Previously, daily dexamethasone treatment (1 mg/kg) was found to attenuate the nephritis and improve survival of NZB/W F1 mice.^[@ref18]^ In the present study, it was used as a benchmark to compare with ZSJ-0228 prodrug treatment. Dose equivalent monthly Dex treatment (28 mg/kg dexamethasone equivalent) was not used as a control due to adverse effects (*e*.*g*., slow movement, eyelids partially closed, changed respiration, hunched posture, and loss of body weight) observed immediately after administration. The approved IACUC protocol requests that animals with such stress behaviors be euthanized immediately to minimize animal discomfort. As anticipated, when tested in NZB/W F1 mice with established nephritis, ZSJ-0228 monthly treatment effectively attenuated albuminuria and maintained 100% animal survival for the entire experiment duration. Dose equivalent daily Dex treatment (1 mg/kg), on the other hand, only presented with moderate efficacy and 80% survival ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). These observations were further supported by the glomerular histologic findings in which ZSJ-0228 treatment was found to more effectively prevent glomerular injury with disease severity rated mostly mild to moderate ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}).

ZSJ-0228 seems to also possess an improved safety profile. As shown in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A, ZSJ-0228 showed minimal cytotoxicity in HK-2 cell culture. During the two-month treatment study, the prodrug treatment did not significantly alter the mice's body weight ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B). Compared to dose equivalent daily Dex treatment, the monthly ZSJ-0228 treatment did not induce osteopenia ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}C--E); neither did it cause immunosuppression, as evidenced by WBC and total serum IgG levels comparable to the saline group ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}F,G). Furthermore, mice treated monthly with ZSJ-0228 were found to have significantly higher adrenal gland mass than the dose equivalent daily Dex-treated mice, suggesting the absence of adrenal gland atrophy ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}H). It is very important to recognize that the WBC reduction induced by GC treatment is being interpreted as immunosuppression in NZB/W F1 mice.^[@ref48]^ It is well-recognized that the opposite effect (*i*.*e*., leukocytosis) is commonly observed in human patients when GC is being used.^[@ref49]^ Therefore, ZSJ-0228's impact on WBCs in the NZB/W F1 mice should not be directly extrapolated to humans. Collectively, these data provide clear evidence of ZSJ-0228's superior therapeutic efficacy to Dex and significantly improved safety when compared to Dex and P-Dex^[@ref19],[@ref34]^ in the treatment of NZB/W F1 mice.

In probing the working mechanism of ZSJ-0228, near-infrared imaging-based *in vivo* biodistribution data ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}A) suggest that the prodrug's main distribution organ in NZB/W F1 mice was the inflamed kidney. The distribution to other organs was limited, which is in stark contrast to the observation in humans treated with dexamethasone (with fast extrarenal elimination and high liver deposition)^[@ref50]^ and in mice with P-Dex (with higher liver and spleen deposition).^[@ref19],[@ref34]^ Different from P-Dex treatment, ZSJ-0228 treatment has no impact on splenomegaly (data not shown), which supports the optical imaging findings. The significantly lower ZSJ-0228 positive cells in other organs counted by the flow cytometry further validated the nephrotropic distribution pattern of ZSJ-0228 ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}B).

Several promising nanoformulations have been developed for dexamethasone delivery.^[@ref51]−[@ref53]^ Comparing to ZSJ-0228, they have the advantage of significantly reduced cost of manufacture and lower barrier for regulatory approval. Similar to P-Dex, their biodistribution patterns favor the MPS system. We speculate that the relatively higher liver/spleen distribution may be attributed to their high molecular weight or large size.^[@ref54]^ ZSJ-0228, on the other hand, is considerably smaller (∼3 kDa). The water-soluble prodrug consists of an mPEG 1900 and two dexamethasone molecules ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). Considering that the hydrodynamic radius of PEG 3000 is around 15 Å,^[@ref55]^ the structurally more compact ZSJ-0228 may be even smaller than that. Our ongoing pharmacokinetic study estimates the *t*~1/2(β)~ of ZSJ-0228 to be around 12 h, which is significantly shorter than that of P-Dex.^[@ref41],[@ref42]^ We believe the relatively smaller size and shorter serum half-life may be the main contributing factor for ZSJ-0228's nephrotropicity and low MPS distribution.

Two additional factors may also be considered in understanding ZSJ-0228's high distribution in the kidney: (1) It has been reported that there is an inverse size dependency in the renal clearance of sub-nanometer gold nanoclusters (AuNCs), which is distinctly different from the general understanding that smaller nanoparticles always clear more rapidly through the kidney than the larger ones.^[@ref56]^ We postulate that the proposed mechanism of physical retention of AuNCs by the glycocalyx of the glomeruli may have also helped to slow down the clearance of ZSJ-0228 from the kidney and thus contributed to its high kidney distribution. (2) According to the ELVIS mechanism, inflammatory cells' accelerated sequestration is one of the major contributors to the high retention of nanomedicine in inflammatory tissues. As shown in [Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}B, the kidney cells of NZB/W F1 mice certainly have demonstrated substantially higher sequestration of ZSJ-0228 than the control NZW mice.

It is interesting to note that ZSJ-0228 was also somewhat retained by kidney/kidney cells of NZW mice ([Figures [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"} and [9](#fig9){ref-type="fig"}). This is probably due to the advanced age (\>28 weeks) of the animals being used in this study. NZB/W F1 mice are the offspring of an NZB female (stock \# 000684, Jackson Laboratory) and an NZW male (stock \# 001058, Jackson Laboratory). Both inbred parental strains may occasionally develop autoimmune abnormalities that are observed in the F1, but not necessarily with the same onset or severity. While the NZW mice have a normal life span, some do develop anti-DNA antibodies, high serum levels of retroviral gp70 antigen, and nephritis at an advanced age.^[@ref23]^

Further flow cytometry profiling of kidney cells that internalize ZSJ-0228 revealed that myeloid cells and proximal tubular epithelial cells were the major players in the sequestration and retention of ZSJ-0228 in the inflamed kidneys of NZB/W F1 mice ([Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}). These findings are not surprising, as infiltrating myeloid cells in LN are known to be phagocytic.^[@ref57]^ It has been reported that inflammatory insults could reprogram the myeloid cells' endocytic machinery from receptor-mediated endocytosis to macropinocytosis,^[@ref58]^ which would accelerate the rate of cell internalization in a receptor-independent fashion. Proximal tubular epithelial cells, on the other hand, recycle the albumin *via* a receptor-mediated endocytosis mechanism when exposed to the proteins.^[@ref59]^ One may suggest that the observed endocytosis of ZSJ-0228 ([Figures [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}--[11](#fig11){ref-type="fig"}) by tubular epithelial cells is a "bystander" effect associated with the internalization/recycling of albumin by the cells. Due to the potential binding of ZSJ-0228 to albumin,^[@ref60],[@ref61]^ it is also possible that the prodrug may piggyback albumin and be internalized through the receptor-mediated endocytic process intended for albumin.

We noticed that while the majority (50%) of renal CD146^+^ cells (endothelial cells) internalized ZSJ-0228 ([Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}B) and IHC analysis suggests a high CD146^+^ cellular uptake of the prodrug ([Figure [10](#fig10){ref-type="fig"}](#fig10){ref-type="fig"}), the flow cytometry data show low prodrug distribution (\<1%) to this cell population ([Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}B). This discrepancy may be attributed to the difficulty in isolating endothelial cells from the kidneys. Typically, a collagenase-based tissue dissociation reagent, Liberase Blendzyme, can be used to efficiently isolate endothelial cells from tissues. Its application, however, often results in damage to other cells.^[@ref62]−[@ref64]^ Thus, a gentler cell isolation protocol was used in the present study. We speculate that this limitation of the current flow cytometry tissue isolation protocol may have inadvertently lowered the number of endothelial cells isolated from the kidney and underestimated their contribution to the kidney sequestration of ZSJ-0228.

While ZSJ-0228 demonstrated strong nephrotropicity on the lupus-prone NZB/W F1 mice, it did not stay in the kidney permanently. The presence of ZSJ-0228 in the kidney decreased over time ([Figures [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"} and [9](#fig9){ref-type="fig"}). This is especially true for the CD11b^+^ myeloid cells isolated from the kidneys of NZB/W F1 mice. The percentage of CD326^+^ cells (proximal tubular epithelium) that internalized ZSJ-0228 did not change from day 1 to day 4 postadministration ([Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}). It has been reported that GC treatment can induce myeloid cell apoptosis.^[@ref65]^ Renal epithelial cells, on the other hand, are insensitive to GC treatment.^[@ref66]^ Therefore, it is possible that the ZSJ-0228 sequestered by myeloid cells may have induced their apoptosis, leading to the prodrug's gradual clearance from the kidney. Since FcR-bearing myeloid cells are responsible for triggering LN,^[@ref67]^ ZSJ-0228's specific sequestration by the myeloid cells in the kidney may also be a plausible explanation for ZSJ-0228's superior efficacy to Dex. Such a notion conforms to the finding shown in [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}, where the number of macrophages was significantly reduced after two months of treatment with ZSJ-0228. Clearly, further investigations are needed to better understand ZSJ-0228's working mechanism on the cellular and molecular levels.

The present study does have its limitations. ZSJ-0228 was designed for the improved efficacy and safety of GC treatment for lupus nephritis, but not for other lupus complications such as arthritis. Since its main distribution organ is the kidney, ZSJ-0228 may not be effective in managing inflammation at other anatomical sites of the body. P-Dex^[@ref17]^ and other GC nanoformulations,^[@ref51]−[@ref53]^ which have longer serum half-lives, may be better suited for these conditions. We speculate that the development of a GC prodrug that would be effective and safe for most of the lupus symptoms may necessitate a macromolecular prodrug system that is conditionally degradable.^[@ref68]^ Regarding the administration route, ZSJ-0228 was given as a monthly i.v. injection in this study. Though the treatment schedule is favorable, the i.v. route would require healthcare professionals for administration in the clinical setting. Previous work^[@ref69]^ indicates that s.c. and i.p. administrated polymeric prodrugs may enter the circulation through the lymphatic system. Therefore, we speculate that it is possible that ZSJ-0228 may also be given *via* these routes and be effective. This approach would enable self-administration of the medication and further improve the patients' compliance to the treatment.

Conclusions {#sec4}
===========

A micelle-forming PEG-based dexamethasone prodrug (ZSJ-0228) was developed with superior and sustained therapeutic efficacy against nephritis in lupus-prone female NZB/W F1 mice. No apparent glucocorticoid side effects were observed. While as a prodrug of dexamethasone, ZSJ-0228 does not change the parent drug's anti-inflammatory and immunosuppressive mechanism on the molecular level, it indeed alters the pharmacology physiologically by restricting its distribution to the inflamed kidneys, providing sustained and localized immunosuppressive and anti-inflammatory effects. We believe ZSJ-0228 can be further developed into a viable drug candidate for the better clinical management of lupus nephritis. We further suggest that this GC prodrug may also be explored for the clinical management of other renal pathologies, such as kidney transplant, IgA nephropathy, focal segmental glomerulosclerosis, minimal change disease, and Goodpasture syndrome, in which GCs are frequently used as first-line therapy.

Methods/Experimental {#sec5}
====================

Materials and Reagents {#sec5.1}
----------------------

Dexamethasone was obtained from Tianjin Pharmaceuticals Group Co., Ltd. (Tianjin, China). Dexamethasone 21-phosphate disodium was purchased from Hawkins, Inc. (Minneapolis, MN, USA). Heterofunctional PEGs were purchased from Rapp Polymere GmbH (Tuebingen, Germany) and Creative PEGWorks (Chapel Hill, NC, USA). Piperidine was purchased from Sigma-Aldrich (St. Louis, MO, USA). Sephadex LH-20 resins were purchased from GE HealthCare (Piscataway, NJ, USA). IRDye 800CW NHS ester was purchased from LI-COR Biosciences (Lincoln, NE, USA). Alexa Fluor 488 NHS ester was obtained from Life Technologies (Carlsbad, CA, USA). The MTT cell proliferation assay was purchased from ATCC (Manassas, VA, USA). Penicillin/streptomycin, trypsin-EDTA, Dulbecco's phosphate-buffered saline (PBS), and RPMI 1640 were from Gibco (Grand Island, NY, USA). Fetal bovine serum was purchased from BenchMark (Gemini Bio-Products, West Sacramento, CA, USA). All solvents and other reagents if not specified were purchased from Fisher Scientific or ACROS and used without further purification.

Instruments {#sec5.2}
-----------

^1^H and ^13^C NMR spectra were recorded on a 500 MHz NMR spectrometer (Varian, Palo Alto, CA, USA). The mass spectrum analyses were performed with an LC/MS/MS system composed of an ACQUITY Ultra Performance LC (UPLC) system (Waters, Milford, MA, USA) and a Sciex 4000 Q TRAP mass spectrometer with an ESI source (Applied Biosystems, Toronto, Canada). HPLC analyses were performed on an Agilent 1100 HPLC system (Agilent Technologies, Inc., Santa Clara, CA, USA) with a reverse phase C~18~ column (Phenomenex, Bondclone H16-441537-C18, 300 × 3.9 mm, 10 μm). *In vivo* near-infrared fluorescence-based optical imaging was accomplished on a LI-COR Pearl Impulse small animal imaging system (Lincoln, NE, USA). Bone qualities were analyzed using a high-resolution Skyscan 1172 micro-CT system (Bruker microCT, Kontich, Belgium). The average hydrodynamic diameter, polydispersity index (PDI), and zeta potential of micelles were determined by DLS experiments using a Zetasizer Nano ZS90 (Malvern Instruments, Worcestershire, UK). The particle size distribution was analyzed using NS300 NanoSight (Malvern Instrument). The micelle morphology was observed using a Tecnai G2 Spirit transmission electron microscope (FEI, Hillsboro, OR, USA) at an acceleration voltage of 100 kV. Digital images were acquired using a KeenView high-resolution camera and analyzed using Soft Imaging Solutions AnalySIS ITEM digital software. The quantification of fluorescence signal intensities of IRDye 800 CW, Alexa Fluor 488, Alexa Fluor 647, and pyrene were measured using a Spectramax M2 spectrofluorometer (Molecular Devices, Sunnyvale, CA, USA). The flow cytometry experiments were performed on a BD LSRII Green flow cytometer (San Jose, CA, USA) and analyzed using the FlowJo software (Treestar, Inc., San Carlos, CA, USA). Confocal microscope images were acquired under an LSM 800 Zeiss Airyscan microscope (Carl Zeiss, Oberkochen, Germany) and analyzed using the ZEN Lite software.

Synthesis of ZSJ-0228 ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}) {#sec5.3}
----------------------------------------------------------------------------------------

### Synthesis of Compound **1** {#sec5.3.1}

Imidazole (2.72 g, 40 mmol) and dexamethasone (7.84 g, 20 mmol) were dissolved in anhydrous *N*,*N*-dimethylformamide (DMF, 40 mL). After the solution was cooled to 0 °C, *tert*-butyldimethylsilyl chloride (TBSCl, 3.3 g, 22 mmol) was added. The solution was maintained at 0 °C for 3 h and at room temperature for 2 h, with constant stirring. Ethyl acetate (100 mL) was then added and washed with brine (80 mL × 4). The organic phase was separated and dried over MgSO~4~. After removal of the solvent, the residue was purified with flash chromatography (ethyl acetate/hexane, 1:2) to produce compound **1** (9.98 g). Yield: 98.5%. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ (ppm) 7.28 (d, *J* = 10.2 Hz, 1H), 6.22 (d, *J* = 10.2 Hz, 1H), 6.00 (s, 1H), 5.29 (s, 1H), 4.97 (s, 1H), 4.78 (d, *J* = 19.1 Hz, 1H), 4.29 (d, *J* = 19.1 Hz, 1H), 4.14 (d, *J* = 10.1 Hz, 1H), 2.91 (m, 1H), 2.61 (td, *J* = 13.6 Hz, 5.8 Hz, 1H), 2.36 (m, 2H), 2.11 (m, 2H), 1.76 (m, 1H), 1.62 (q, *J* = 11.8 Hz, 1H), 1.48 (s, 3H), 1.41 (d, *J* = 13.5 Hz, 1H), 1.33 (m, 1H), 1.06 (m, 1H), 0.88 (s, 9H), 0.87 (s, 3H), 0.77 (d, *J* = 7.2 Hz, 3H), 0.04 (s, 3H), 0.03 (s, 3H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ (ppm) 209.19, 185.45, 167.20, 152.94, 129.17, 124.29, 101.38 (d, *J*~C--F~ = 174 Hz), 90.52, 70.84 (d, *J*~C--F~ = 36.9 Hz), 68.14, 48.13 (d, *J*~C--F~ = 22.5 Hz), 47.65, 36.03, 35.33, 33.82 (d, *J*~C--F~ = 19.3 Hz), 32.09, 30.46, 27.42, 25.97, 23.11, 23.08, 18.34, 16.86, 15.38, −4.89, −5.04. MS (ESI): *m*/*z* 507.2 (M + H^+^), calculated 506.3.

### Synthesis of Compound **2** {#sec5.3.2}

NH~2~NH~2~ monohydrate (750 mg, 15 mmol) and compound **1** (2.53 g, 5 mmol) from the first step were dissolved in methanol (25 mL). After addition of acetic acid (60 mg, 1 mmol), the solution was stirred at room temperature for 5 h. Ethyl acetate (100 mL) was then added, and the solution was washed with brine (80 mL × 4). The organic phase was separated and dried over MgSO~4~. After solvent removal with rotary evaporation, the residue was purified with flash chromatography (ethyl acetate/hexane, 1:1) to produce compound **2** (1.14 g). Considering the recovery of unreacted compound **1** (1.24 g), we calculate the final yield at 85.8%. Because of the hydrazone bond formation, a mixture of two syn/anti configurational isomers exists in the product. However, they are indistinguishable on flash chromatography. The two isomers' molar ratio was determined to be 1.63:1 according to ^1^H NMR. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ (ppm) 6.67 (d, *J* = 10.4 Hz, 0.38H), 6.39 (s, 0.62H), 6.28 (d, *J* = 10.4 Hz, 0.38H), 6.23 (s, 2H), 6.03 (d, *J* = 11.5 Hz, 0.62H), 5.98 (d, *J* = 11.5 Hz, 0.62H), 5.76 (s, 0.38H), 5.09 (dd, *J* = 10.5 Hz, 3.0 Hz, 1H), 4.96 (s, 1H), 4.74 (d, *J* = 19.1 Hz, 1H), 4.26 (d, *J* = 19.1 Hz, 1H), 4.09 (m, 1H), 2.87 (m, 1H), 2.50 (m, 1H), 2.22 (m, 1H), 2.16 (m, 3H), 1.58 (m, 2H), 1.36 (s, 3H), 1.33 (d, *J* = 13.5 Hz, 1H), 1.26 (m, 1H), 1.02 (m, 1H), 0.85 (s, 9H), 0.81 (s, 3H), 0.74 (d, *J* = 7.2 Hz, 3H), 0.02 (s, 3H), 0.01 (s, 3H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ (ppm) 209.71, 170.98, 151.16, 144.73, 140.74, 140.62, 139.03, 132.91, 127.70, 121.61, 116.17, 110.81, 100.71 (d, *J*~*C--F*~ = 171.9 Hz), 100.50 (d, *J*~*C--F*~ = 171.9 Hz), 90.92, 90.87, 70.00 (d, *J*~C--F~ = 37.4 Hz), 69.93 (d, *J*~C--F~ = 37.3 Hz), 68.43, 60.29, 47.21 (d, *J*~C--F~ = 22.8 Hz), 47.05 (d, *J*~C--F~ = 22.8 Hz), 44.02, 36.41, 36.35, 35.62, 34.40 (d, *J*~C--F~ = 19.5 Hz), 34.36 (d, *J*~C--F~ = 19.5 Hz), 25.28, 25.24, 24.85, 24.82, 21.17, 18.58, 17.15, 15.63, 14.49, −4.67, −4.80. MS (ESI): *m*/*z* 521.5 (M + H^+^), calculated 520.3. LC/MS: two peaks in the chromatography with the retention times at 5.74 and 6.32 min were found to have the same molecular weight at 521.356 (conditions: A: 7.5 mM ammonium acetate; B: 95% MeOH and 5% acetonitrile; A:B = 30:70).

### Synthesis of Compound **3** {#sec5.3.3}

4-Dimethylaminopyridine (201 mg, 1.65 mmol) and compound **2** (2.86 g, 5.5 mmol) were dissolved in anhydrous DMF (15 mL). After cooling to 0 °C, Fmoc-glycine (2.12 g, 7.15 mmol) and dicyclohexylcarbodiimide (DCC, 1.70 g, 8.25 mmol) were added. The resulting solution was stirred at 0 °C for 3 h. Ethyl acetate (100 mL) was then added, and the solution was washed with brine (80 mL × 4). The organic phase was separated and dried over MgSO~4~. After removal of the solvent, the residue was purified by flash chromatography (ethyl acetate/hexanes, 1:1) to produce crude compound **3** (3.72 g). The yield is 84.5%. TLC indicates the presence of a small amount of side products, which were difficult to separate. The crude product was used directly in the next reaction.

### Synthesis of Compound **4** {#sec5.3.4}

Compound **3** (3.0 g, 3.75 mmol) was dissolved in dichloromethane (DCM, 10 mL) and then cooled to 0 °C. After addition of piperidine (1 mL), the solution was stirred at 0 °C for 3 h. Ethyl acetate (100 mL) was then added and washed with brine (80 mL × 3). The organic phase was separated and dried over MgSO~4~. After removal of the solvent, toluene (50 mL) was added and then evaporated to help remove the residual piperidine. After purification with flash chromatography (ethyl acetate followed by ethyl acetate/methanol, 2:1), 1.96 g of compound **4** was produced. The yield is calculated as 90.6%. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ (ppm) 7.01 (d, *J* = 10.3 Hz, 0.23H), 6.86 (d, *J* = 10.3 Hz, 0.16H), 6.77 (s, 0.26H), 6.66 (d, *J* = 10.3 Hz, 0.17H), 6.60 (d, *J* = 10.3 Hz, 0.23), 6.59 (s, 0.25H), 6.46 (d, *J* = 10.3 Hz, 0.26H), 6.41 (d, *J* = 10.3 Hz, 0.26H), 6.28 (d, *J* = 10.3 Hz, 0.25H), 6.19 (d, *J* = 10.3 Hz, 0.26H), 6.02 (s, 0.16H), 5.92 (s, 0.20H), 5.21 (br, 1H), 4.98 (br s, 1H) 4.77 (d, *J* = 19.0 Hz, 1H), 4.28 (d, *J* = 19.0 Hz, 1H), 4.12 (m, 1.0H), 3.25 (s, 2H), 2.90 (m, 1H), 2.60 (m, 1H), 2.25 (m, 2H), 2.14 (m, 1H), 1.71 (m, 1H), 1.58 (m, 1H), 1.41 (d, *J* = 8.6 Hz, 3H), 1.38 (d, *J* = 13.5 Hz, 1H), 1.32 (m, 1H), 1.05 (m, 1H), 0.88 (s, 9H), 0.77 (d, *J* = 7.1 Hz, 3H), 0.04 (s, 3H), 0.02 (s, 3H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ (ppm) 209.44, 174.80, 169.60, 157.62, 156.88, 152.11, 151.27, 146.38, 146.05,144.35, 143.81, 142.95, 139.56, 138.87, 126.74, 120.70, 116.73, 116.67, 111.46, 111.32, 100.98 (d, *J*~C--F~ = 173.4 Hz), 100.91 (d, *J*~C--F~ = 172.3 Hz), 100.76 (d, *J*~C--F~ = 173.4 Hz), 100.73 (d, *J*~C--F~ = 172.6 Hz), 90.72, 90.66, 70.13 (d, *J*~C--F~ = 37.4 Hz), 70.12 (d, *J*~C--F~ = 37.3 Hz), 68.28, 47.74, 47.49 (d, *J*~C--F~ = 21.5 Hz), 47.45 (d, *J*~C--F~ = 21.5 Hz), 47.23, 44.15, 43.77, 42.72, 36.22, 36.17, 34.10 (d, *J*~C--F~ = 19.5 Hz), 32.16, 31.19, 31.06, 30.20, 30.05, 27.58, 26.08, 24.55, 24.51, 24.19, 24.16, 24.10, 24.06, 18.45, 16.99, 15.52, 15.50, −4.79, −4.93. MS (ESI): *m*/*z* = 578.3 (M + H^+^), calculated 577.3. LC/MS: two peaks in the chromatogram with the retention times at 3.91 and 4.47 min were found to have the same molecular weight at 578.347 (conditions: A: 7.5 mM ammonium acetate, B: 95% MeOH and 5% acetonitrile; A:B = 30:70).

### Synthesis of Compound **5** {#sec5.3.5}

Compound **4** (444 mg, 0.768 mmol) was dissolved in anhydrous DMF (3 mL), followed by the addition of Fmoc-glutamic acid (135 mg, 0.366 mmol), hydroxybenzotriazole (HOBt, 148 mg, 1.098 mmol), and DCC (226 mg, 1.098 mmol). The resulting solution was stirred at room temperature for 4 h. Ethyl acetate (100 mL) was then added to the solution and washed with brine (80 mL × 3). The organic phase was separated and dried over MgSO~4~. After the solvent removal, the residue was purified by flash chromatography (ethyl acetate/methanol, 10:1) to afford crude compound **5** (471 mg). The yield is 86.5%. TLC indicates the presence of a small amount of side products, which were difficult to separate. The crude product was used directly in the next reaction.

### Synthesis of Compound **6** {#sec5.3.6}

Compound **5** (450 mg, 0.3 mmol) was dissolved in DCM (4.5 mL) and cooled to 0 °C. After addition of piperidine (1.5 mL), the resulting solution was stirred at 0 °C for 3 h. Ethyl acetate (100 mL) was then added and washed with brine (80 mL × 3). The organic phase was separated and dried over MgSO~4~. After solvent removal, the residue was purified by flash chromatography (ethyl acetate followed by ethyl acetate/methanol, 3:1) to produce compound **6** (330 mg). The yield is 86.4%. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ (ppm) 10.83 (m, 1.12H), 10.64 (m, 0.80H), 8.38 (m, 0.30H), 8.28 (m, 0.62H), 8.18 28 (m, 0.42H), 7.99 (m, 0.60H), 7.01 (m, 0.29H), 6.93 (m, 0.16H), 6.77 (s, 0.91H), 6.68 (s, 0.73H), 6.62 (m, 0.34H), 6.45 (m, 1.52H), 6.25 (m, 1.53H), 6.01 (s, 0.15H), 5.96 (0.31H), 5.17 (s, 1.0H), 5.15 (s, 1.0H), 4.95 (s, 2H), 4.77 (d, *J* = 19.1 Hz, 2.0H), 4.28 (d, *J* = 19.1 Hz, 2.0H), 4.19 (m, 0.53H), 3.95--4.15 (m, 4.91H), 3.70--3.90 (m, 1.68H), 3.26 (m, 1.54H), 2.90 (m, 2.15H), 2.55--2.75 (m, 3.93H), 2.15--2.35 (m, 5.23H), 2.05--2.15 (m, 5.04H), 1.87 (m, 1.10H), 1.72 (m, 3.07H), 1.59 (m, 2.23H), 1.41 (m, s, 6.87H), 1.31 (m, 3.38H), 1.05 (m, 1.99H), 0.87 (s, 18H), 0.85 (s, 6H), 0.77 (d, *J* = 6.9 Hz), 0.03 (s, 6H), 0.02 (s, 6H). MS (ESI): *m*/*z* 1266.4 (M + H^+^), calculated 1265.7. LC/MS: three peaks in the chromatogram with the retention times at 5.07, 5.80, and 6.54 min were found to have the same molecular weight of 1266.782 (conditions: A: 7.5 mM ammonium acetate, B: 95% MeOH and 5% acetonitrile; A:B = 18:82).

### Synthesis of ZSJ-0228 {#sec5.3.7}

DCC (107 mg, 0.52 mmol), HOBt (70.2 mg, 0.52 mmol), and mPEG-COOH (100 mg, 0.052 mmol) were dissolved in anhydrous DMF (3 mL) at room temperature and stirred for 1 h. After addition of compound **6** (428 mg, 0.338 mmol), the solution was stirred at room temperature for 24 h. An LH-20 column was used to obtain the polymer fraction. After removal of the solvent, the polymeric residue was dissolved in tetra-*n*-butylammonium fluoride (1 M, 2 mL) and stirred for 2 h. The resulting solution was again applied to an LH-20 column to separate the polymeric fraction. After dialysis against DI water overnight (MWCO = 2 kDa), the solution was lyophilized to produce ZSJ-0228 (118.7 mg). The yield is 77.8%. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ (ppm) 10.95 (s, 0.28H), 10.91 (s, 0.27H), 10.86 (s, 0.80H), 10.82 (s, 0.37H), 10.58 (m, 0.67H), 8.39 (m, 0.35H), 8.21 (s, 0.59H), 8.14 (m, 0.35H), 7.99 (m, 0.61H), 7.78 m, 0.30H), 7.71 (m, 0.69H), 7.54 (m, 0.1H), 7.02 (d, *J* = 10.3 Hz, 0.53H), 6.90 (m, 0.26H), 6.78 (s, 0.69H), 6.60--6.71 (m, 1.25H), 6.42--6.47 (m, 1.14H), 6.27 (m, 0.41H), 6.21 (m, 0.73H), 6.00 (m, 0.26H), 5.96 (s, 0.53H), 5.14 (m, 1.98H), 4.93 (s, 1.85H), 4.66(m, 1.86H), 4.48 (dd, *J* = 19.2 Hz, 5.8 Hz, 1.80H), 4.40 (m, 0.67H), 4.34 (m, 0.40H), 4.00--4.25 (m, 6.66H), 3.92 (s, 2.55H), 3.86 (m, 0.52H), 3.83 (m, 0.36H), 3.51 (m, 183H), 3.25 (s, 3.24H), 2.93 (m, 1.92H), 2.63 (m, 1.43H), 2.36 (m, 0.66H), 2.20--2.35 (m, 5.71H), 2.05--2.15 (m, 4.46H), 1.97 (m, 1.45H), 1.84 (m, 1.16H), 1.71 (m, 2.15H), 1.60 (m, 2.48H), 1.42 (s, 7.95H), 1.31 (m, 2.55H), 1.23 (s, 1.07H), 1.05 (m, 2.12H), 0.84 (s, 6.00H), 0.77 (d, *J* = 7.1 Hz, 5.74H). MS (ESI): Two clusters of peaks were observed. One cluster is at around 1550, which are diion peaks. For example: *n* = 44, calculated: (M~*n*=44~ + 2Na^+^)/2 = 1546.4, found 1546.7; *n* = 40, calculated: (M~*n*=40~ + 2Na^+^)/2 = 1458.38, found 1458.3. The other cluster is at around 1100, which are triion peaks, *n* = 46 calculated (M~*n*=46~ + 3Na^+^)/3 = 1068.0, found 1068.5. MS (MALDI-TOF): One symmetric cluster of peaks (at about 3000) was observed, which represent the molecular weights of ZSJ-0228 plus sodium ion. For example: M~*n*=41~ + Na^+^ = 2937.83, found 2938.28; M~*n*=43~ + Na^+^ = 3025.84, found 3026.342; M~*n*=47~ + Na^+^ = 3201.96, found 3202.425.

Synthesis of Fluorescent-Labeled ZSJ-0228 {#sec5.4}
-----------------------------------------

The synthetic routes for IRDye 800CW-, Alexa Fluor 488-, and Alexa Fluor 647-labeled ZSJ-0228 are similar to the unlabeled ZSJ-0228 ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}), except the mPEG-COOH was replaced with Fmoc-NH-PEG-COOH. After Fmoc deprotection, the resulting NH~2~-containing polymeric prodrug (100 mg) was dissolved in anhydrous DMF (1 mL) together with the NHS esters of IRDye 800CW (1 mg), Alexa Fluor 488 (1 mg), or Alexa Fluor 647 (1 mg). The solution was stirred at room temperature for 15 h. After LH-20 column purification, the fluorescent-labeled prodrugs were obtained. Using a Spectramax M2 spectrofluorometer, the IRDye 800CW, Alexa Fluor 488, and Alexa Fluor 647 contents were determined as 126.94 ± 0.75, 145.88 ± 3.1, and 85.13 ± 1.49 μmol/g, respectively.

Micelle Characterization {#sec5.5}
------------------------

The pyrene-based fluorescence probe method was used to determine the CMC of ZSJ-0228. For sample preparation, a stock solution of pyrene (0.02 mg/mL, in acetone) was added to a 96-well plate. After adding the aqueous solution of ZSJ-0228 at different concentrations to the wells, the plate was left at room temperature for 2 h to allow acetone evaporation. The final pyrene concentration was maintained at 0.6 μM, which is slightly below its water solubility at room temperature. After transferring to a quartz 96-well plate, the fluorescence intensity was measured using a fluorescence microplate spectrofluorometer. The excitation wavelength was set at 334 nm, and the emission wavelength at 373 nm (I1) and 384 nm (I3). The ratio of fluorescence intensity I1/I3 was plotted against prodrug concentration to obtain the CMC value.^[@ref70]^

The hydrodynamic diameter (*D*~h~), ζ-potential, and PDIs of micelles were determined with a Malvern Zetasizer Nano-ZS at 25 °C at a 90° angle in triplicate. ZSJ-0228 was dissolved in ddH~2~O at designed concentrations, filtered through a 20 μm syringe filter, and vacuumed in the desiccator for 10 min to eliminate air bubbles before measurement. Data were analyzed by the Zetasizer software version 7.12.

The concentration and the size distribution of micelles were determined using an NS300 NanoSight with a low-volume flow cell plate and a 405 nm laser. The micelle solutions were pumped into the chamber using the installed syringe pump. The measurements were conducted at room temperature, replicated five times, and further analyzed using the NTA analytical software, version 3.2. Each video sequence was captured over 60 s.

To understand the micelle morphology, TEM was used to visualize micelles at 80 kV. For sample preparation, one drop of the ZSJ-0228 micelle solution (2 mg/mL) was deposited on the Formvar/silicone monoxide-coated 200 mesh copper grid surface and then dried overnight at room temperature. The analysis was performed at 25 °C.

To quantify the dexamethasone content in ZSJ-0228, the prodrug was dissolved in HCl (0.5 mL, 0.1 N) and stirred overnight at room temperature. The sample (50 μL) was withdrawn and neutralized by addition of NaOH (50 μL, 0.1 N), then diluted in acetonitrile (0.9 mL). The sample (in triplet) was analyzed using an Agilent 1100 HPLC system equipped with a reverse phase C~18~ column (Phenomenex, Bondclone H16-441537-C~18~, 300 × 3.9 mm, 10 μm). Mobile phase: acetonitrile/water, 30:70; detection wavelength, 240 nm; flow rate, 1 mL/min; injection volume, 10 μL. The dexamethasone content in ZSJ-0228 was then calculated based on the HPLC analysis result.

To understand the impact of pH values on the release of dexamethasone from ZSJ-0228, the prodrug (3 mg/mL) was dissolved in acetate buffers (pH = 4.5, 5.0, 6.5, and 7.4). Pluronic F127 (1 w/v % of buffer) was added as a surfactant to create the "sink" condition.^[@ref71]^ The micelle solutions were incubated at 37 °C with gentle agitation (60 r/min). At selected time points, the sampled releasing solution (0.1 mL) was neutralized with NaOH (0.1 N) and analyzed with HPLC in triplicate. The experiment was repeated three times in each pH buffer. The accumulative release of dexamethasone from ZSJ-0228 micelles was calculated according to the following equation, where 2 mL refers to the total volume of release medium, 0.1 mL is the sampling volume, and *C~n~* refers to the concentration of dexamethasone at sampling time point *n*.

Evaluation of ZSJ-0228's Therapeutic Efficacy on NZB/W F1 Mice {#sec5.6}
--------------------------------------------------------------

Beginning at 20 weeks of age, NZB/W F1 female mice (Jackson Laboratories, Bar Harbor, ME, USA) were randomized into three groups (saline control, Dex, and ZSJ-0228). The urine protein level was monitored weekly using Albustix reagent strips (Siemens Healthineers, Erlangen, Germany). Only mice with established nephritis, as evidenced by sustained albuminuria (≥100 mg/dL) over 2 weeks, were enrolled in the study. ZSJ-0228 treatment (106 mg/kg, containing 28 mg/kg of dexamethasone, *n* = 10) and saline (*n* = 12) were administered as a monthly i.v. injection. A total of two injections of ZSJ-0228 were given during the two-month treatment period. The Dex treatment (dexamethasone 21-phosphate disodium, 1.32 mg/kg, containing 1.00 mg/kg of dexamethasone, *n* = 11) was given as a daily i.v. injection. All treatments continued for 8 weeks. The body weight and proteinuria level of the animals were monitored weekly. Every 4 weeks, peripheral blood was sampled from the saphenous vein for serum analyses. Mice that developed severe proteinuria (≥2000 mg/dL) or showed signs of distress (*e*.*g*., reduced mobility, weight loss \>20%, edema, unkempt appearance) were sacrificed immediately. At two months post-treatment initiation, all surviving mice were euthanized by CO~2~ asphyxiation, with major tissues and organs isolated, weighed, and processed at necropsy. The animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Nebraska Medical Center (UNMC).

Histological Evaluation {#sec5.7}
-----------------------

Paraffin sections of the mouse kidneys were deparaffinized, rehydrated, washed with water, and stained with periodic acid--Schiff for evidence of glomerulonephritis by light microscopy. Glomerulonephritis was assessed by a pathologist (K.W.F.) using a semiquantitative scale as described previously.^[@ref20]^ Briefly, a score of 0 represents healthy condition; a score of 1 represents mild focal disease; a score of 2 represents moderate focal disease; scores of 3 and 4 represent diffuse disease (namely, severe glomerulonephritis). Scores of 0, 1, 2, 3, and 4 indicate that 0, 1--19, 20--50, 51--75, and \>75% of the glomeruli were affected. Fifty glomeruli per mouse were evaluated.

Immune complexes and macrophage infiltration were observed *via* immunohistochemistry. Rabbit anti-mouse IgG (Abcam) and rabbit anti-mouse F4/80 IgG (Abcam) were used as the primary antibodies. After deparaffinization and rehydration, a rabbit-specific HRP/DAB (ABC) detection IHC kit (Abcam) was applied. Briefly, the slides were first incubated in pH 6.0 citrate buffer (0.1 M), washed, and then incubated in H~2~O~2~. The slides were blocked and incubated with the primary antibodies. Antibody binding was visualized using the DAB chromogen. The staining intensity (represented as arbitrary gray units) of 50 glomeruli per mouse was quantified using Zeiss AxioVision software (version 4.6.3.0). Another set of slides stained for immune complexes and macrophages were counterstained with hematoxylin; these slides were used for illustration purposes only.

For confocal microscopy, kidneys were dissected, fixed, dehydrated, and frozen in 2-methylbutane in a dry ice bath. Sections (20 μm) were cut on a Bright's cryostat (Bright Instrument Co., Huntingdon, UK), thaw-mounted onto slides, and stored at −80 °C until stained. The sections were stained with anti-mouse CD11b (Santa Cruz), CD 133 (Abcam), and CD146 (Abcam) and then incubated with Alexa Fluor 488-labeled secondary antibody (Thermo Fisher Scientific, Bremen). Cells were visualized *via* immunofluorescence under a Zeiss LSM 800 confocal microscope. The images were processed using the Carl Zeiss Zen 2.3 software.

Analysis of Bone Quality {#sec5.8}
------------------------

Femoral bone quality was analyzed using a Skyscan 1172 micro-CT system. The scanning parameters were set as follows: voltage 48 kV, current 187 μA, exposure time 620 ms, resolution 6.07 μm, and aluminum filter 0.5 mm. Three-dimensional reconstructions were achieved using the NRecon and DataViewer software (Bruker micro-CT). A consistent polygonal region of interest of trabecular bone at the distal femur, from 20 slices (0.25 mm) to 100 slices proximal (1.25 mm) to the growth plate, was selected for bone quality analysis. The mean bone mineral density, bone volume/tissue volume, trabecular number, and thickness were quantified using the Bruker CTAn software.

Analysis of Serum Immunoglobulin and Autoantibody Levels {#sec5.9}
--------------------------------------------------------

Serum levels of immunoglobulin were assessed *via* an enzyme-linked immunosorbent assay (ELISA). Total serum IgG levels were measured using a commercial ELISA kit (Innovation Research, Novi, MI, USA). Serum anti-dsDNA IgG levels were determined by ELISA (Alpha Diagnostic, San Antonio, TX, USA) as described previously.^[@ref34]^

Near-Infrared Optical Imaging {#sec5.10}
-----------------------------

After the proteinuria was established, NZB/W F1 mice and NZW mice were given ZSJ-0228-IRDye (IRDye 800 CW dose of 148 nmol/kg, dexamethasone equivalent dose of 28 mg/kg) *via* tail vein injection. At selected time points (1 and 4 days postinjection), the mice were euthanized and perfused with saline. All major organs (*i*.*e*., heart, lungs, liver, spleen, kidneys, and adrenal gland) were isolated and imaged using a LI-COR Pearl Impulse imager. The two imaging time points (1 and 4 days postinjection) were selected to avoid the early dynamic distribution phase when the prodrug concentrations in different organs and tissues change dramatically within a short period of time. All images were collected under the channel of 800 nm with the same resolution (170 μm) settings.

Flow Cytometry Analysis {#sec5.11}
-----------------------

After the proteinuria was established, NZB/W F1 mice (*n* = 3 for each time point) and NZW mice (*n* = 5 for each time point) were given ZSJ-0228-AF647 (Alexa Fluor 647 dose of 300 nmol/kg, dexamethasone equivalent dose of 28 mg/kg) *via* tail vein injection. The animals were euthanized and perfused at 1 and 4 days postadministration. Blood, bone marrow, heart, lungs, kidneys, liver, and spleen were harvested and processed to obtain single-cell suspensions. These cells were marked by the following antibodies: BV711-labeled anti-mouse CD11b, BV786-labeled anti-mouse CD3e, BUV395-labeled anti-mouse NK1.1, PerCP-Cy5.5 labeled-CD146, PE-Cy7-labeled CD19, BV510-labeled anti-mouse CD11c, APC-eFluor 780-labeled anti-mouse Ly-6G (BD Biosciences), APC-labeled anti-mouse F4/80 and PE-labeled anti-mouse CD326 (eBioscience Inc.). The cells were then analyzed using a BD LSR II Green flow cytometer with FlowJo software.

Cell Culture Study {#sec5.12}
------------------

The cell viability was quantified using the 3-\[4,5-dimethylthiazol-2-yl\]-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay from ATCC. Briefly, human proximal tubule epithelial (HK-2) cells^[@ref28]^ were seeded in 96-well plates (1 × 10^4^ cells/well) overnight and treated with different concentrations of ZSJ-0228 (0.01--2000 μM dexamethasone equivalent), Dex (0.01--2000 μM dexamethasone equivalent), and mPEG (0.005--1000 μM ZSJ-0228 equivalent). PBS was used as a control. The cells were incubated for 24, 48, and 72 h. At each time point, 10 μL of MTT was added to each well and incubated at 37 °C for 4 h. MTT detergent reagent (100 μL/well) was added to dissolve the insoluble formazan, then incubated for 2 h in the dark at room temperature. A microplate reader (Fisherbrand accuSkan FC filter-based microplate photometer) was then used to measure the UV absorbance at 570 and 660 nm (reference wavelength). The cell viability results are presented as the percentage of PBS control (100%).

To investigate the internalization of Alexa Fluor 488-labeled ZSJ-0228 (ZSJ-0228-AF488), HK-2 cells were seeded on a 24-well plastic plate and incubated overnight with LPS (10 μg/mL) to mimic the lupus nephritis condition. ZSJ-0228-AF488 (final concentration of 200 μg/mL) was added to LPS-stimulated HK-2 cells. The HK-2 cells without LPS treatment were used as controls. At 1, 4, 24, 48, and 72 h time intervals, the cells were rinsed, fixed, and analyzed using a flow cytometer.

For the subcellular localization studies, HK-2 cells were cultured overnight with LPS and then incubated with ZSJ-0228-AF488 (200 μg/mL) for 24 h on glass coverslips in the 24-well plates. Cells were rinsed and incubated with LysoTracker DND-99 (Invitrogen, 75 nM) for 3 h. Then the cells were rinsed, stained with DAPI, fixed, mounted, and observed under a confocal microscope.

Statistical Analysis {#sec5.13}
--------------------

IBM SPSS 17.0 (IBM Corp., Armonk, NY, USA) or SAS 9.4 (SAS Institute, Cary, NC, USA) were used for statistical analyses in this study. Continuous outcomes were compared among ≥3 groups using the analysis of variance (ANOVA) or Kruskal--Wallis tests. Tukey's *post hoct* test or the Mann--Whitney U test with the Bonferroni method for multiple comparisons was used for the pairwise comparisons. The outcome of survival rate was compared among three groups using the log-rank test. Multiple comparisons were corrected with Bonferroni's method. The binary outcome of having proteinuria reading values of 2 and above at the 8-week time point was compared among the three groups using Fisher's exact test. Bonferroni's pairwise comparison was used to control for multiple testing. The generalized estimating equation (GEE) method was used to model the repeated measurements of a continuous outcome to account for the correlation within the subject. The GEE method is robust to the misspecification of the distribution of the outcome. Tukey's pairwise comparison between groups was performed to control for multiple testing in the GEE model.
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